Literature DB >> 24891252

[Role of orthopedic rheumatologist in the therapy of rheumatic diseases with biologics].

S Rehart1, M Henniger.   

Abstract

The international strategies in the treatment of rheumatic diseases have changed dramatically in the last 10 years. In addition to the prescription of a basic medication as soon as possible, biologics are increasingly being used for drug treatment of rheumatic diseases in Germany. The domains of orthopedic surgeons and orthopedic rheumatologists are still the extended conservative and surgical treatment of inflammatory systemic diseases, which continue to play an important role despite the improved drug therapy options. Orthopedic surgeons should principally be familiar with the use of antirheumatic drugs, especially with respect to the perioperative management. However, there is also a role for the orthopedic surgeon in the early detection of inflammatory systemic diseases and in cooperation with rheumatologists in the medicinal treatment of selected diseases. Because patients with initial stages of joint pain, e.g. from rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthropathy often present first to an orthopedic surgeon, recognition of the early stages by the primary treating physician, including the necessary rapid induction of drug therapy is especially important. In addition there is a shortage of internist rheumatologists in Germany so that selective referral and close cooperation between the two physicians become of great importance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24891252     DOI: 10.1007/s00132-014-2321-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  15 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

3.  [Perioperative use of biologicals in rheumatoid arthritis].

Authors:  F Heldmann; F Dybowski; X Baraliakos; J Braun
Journal:  Z Rheumatol       Date:  2011-01       Impact factor: 1.372

4.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; L Brandt; E Baecklund; L Bertilsson; N Feltelius; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

5.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

Review 6.  The risk of malignancies in RA patients treated with biologics.

Authors:  J Askling
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

7.  Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.

Authors:  T Pincus; L F Callahan; W G Sale; A L Brooks; L E Payne; W K Vaughn
Journal:  Arthritis Rheum       Date:  1984-08

8.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

9.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

10.  Long-term outcome of treating rheumatoid arthritis: results after 20 years.

Authors:  D L Scott; D P Symmons; B L Coulton; A J Popert
Journal:  Lancet       Date:  1987-05-16       Impact factor: 79.321

View more
  3 in total

1.  [Therapeutic options in juvenile idiopathic arthritis : Surgical and conservative orthopedic rheumatological treatment].

Authors:  J-P Haas; M Arbogast
Journal:  Z Rheumatol       Date:  2021-04-21       Impact factor: 1.372

Review 2.  [Treatment options in juvenile idiopathic arthritis : Part 2: Orthopedics und surgery].

Authors:  M Arbogast; J-P Haas
Journal:  Orthopade       Date:  2018-11       Impact factor: 1.087

Review 3.  [Juvenile rheumatoid diseases: Endoprosthetic care of destroyed hip joints].

Authors:  S Rehart; M Henniger
Journal:  Orthopade       Date:  2015-07       Impact factor: 1.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.